Cadence Pharmaceuticals Inc. (
Q3 2010 Earnings Call
November 5, 2010 8:30 AM ET
Ted Schroeder – President and CEO
Jim Breitmeyer – Executive Vice President and CMF
Scott Byrd – Senior Vice President and CCO
Bill LaRue – Senior Vice President and CFO.
Charles Duncan – JMP Securities
Eric Schmidt – Cowen and Company
Adam Cutler – Canaccord Genuity
Joseph Schwartz – Leerink Swann
Irina Rivkind – Duncan Williams
Richard Lau – Wedbush Securities
Good morning. And welcome to the Cadence Pharmaceuticals Third Quarter 2010 Financial Results Conference Call. On the call today are Ted Schroeder, President and CEO; Jim Breitmeyer, Executive Vice President and Chief Medical Officer; Scott Byrd, Senior Vice President and Chief Commercial Officer; and Bill LaRue, Senior Vice President and Chief Financial Officer.
At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the company we will open the conference for question-and-answer after the management presentation. (Operator Instructions)
Our first speaker is Bill LaRue. Please go ahead, sir.
Thank you. Good morning, everyone. Before we get started today, I’d like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Such forward-looking statements include statements regarding our readiness for and anticipated timing for the planned commercial launch of OFIRMEV, OFIRMEV’s market potential and ability to fulfill unmet medical needs, our beliefs that pharmacoeconomic issues will not be a significant barrier to formulary approvals, the sufficiency of our company’s capital resources to fund our operations through the launch of OFIRMEV and our financial estimates or projections.